Smart Rosanna, Kase Courtney A, Taylor Erin A, Lumsden Susan, Smith Scott R, Stein Bradley D
RAND Corporation, Santa Monica, CA, United States.
RAND Corporation, Pittsburgh, PA, United States.
Prev Med Rep. 2019 Nov 6;17:101015. doi: 10.1016/j.pmedr.2019.101015. eCollection 2020 Mar.
Better opioid prescribing practices, promoting effective opioid use disorder treatment, improving naloxone access, and enhancing public health surveillance are strategies central to reducing opioid-related morbidity and mortality. Successfully advancing and evaluating these strategies requires leveraging and linking existing secondary data sources. We conducted a scoping study in Fall 2017 at RAND, including a literature search (updated in December 2018) complemented by semi-structured interviews with policymakers and researchers, to identify data sources and linking strategies commonly used in opioid studies, describe data source strengths and limitations, and highlight opportunities to use data to address high-priority public health research questions. We identified 306 articles, published between 2005 and 2018, that conducted secondary analyses of existing data to examine one or more public health strategies. Multiple secondary data sources, available at national, state, and local levels, support such research, with substantial breadth in data availability, data contents, and the data's ability to support multi-level analyses over time. Interviewees identified opportunities to expand existing capabilities through systematic enhancements, including greater support to states for creating and facilitating data use, as well as key data challenges, such as data availability lags and difficulties matching individual-level data over time or across datasets. Multiple secondary data sources exist that can be used to examine the impact of public health approaches to addressing the opioid crisis. Greater data access, improved usability for research purposes, and data element standardization can enhance their value, as can improved data availability timeliness and better data comparability across jurisdictions.
改善阿片类药物处方做法、促进有效的阿片类药物使用障碍治疗、改善纳洛酮获取途径以及加强公共卫生监测,是降低阿片类药物相关发病率和死亡率的核心策略。成功推进和评估这些策略需要利用和链接现有的二手数据源。2017年秋季,我们在兰德公司开展了一项范围界定研究,包括文献检索(2018年12月更新),并辅以对政策制定者和研究人员的半结构化访谈,以确定阿片类药物研究中常用的数据源和链接策略,描述数据源的优势和局限性,并突出利用数据解决高度优先的公共卫生研究问题的机会。我们确定了2005年至2018年间发表的306篇文章,这些文章对现有数据进行了二次分析,以检验一项或多项公共卫生策略。国家、州和地方各级可获取的多个二手数据源支持此类研究,在数据可用性、数据内容以及数据随时间支持多层次分析的能力方面具有广泛的范围。受访者确定了通过系统增强来扩展现有机能的机会,包括为各州创建和促进数据使用提供更多支持,以及关键的数据挑战,如数据可用性滞后以及随着时间推移或跨数据集匹配个体层面数据的困难。存在多个可用于检验公共卫生方法应对阿片类药物危机影响的二手数据源。更大的数据获取、提高研究目的的可用性以及数据元素标准化可以提升其价值,数据可用性及时性的改善以及跨辖区更好的数据可比性也可以提升其价值。